RESUMO
UNLABELLED: Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits. CLINICAL TRIALS REGISTRATION: NCT 01543958.
Assuntos
Translocação Bacteriana , Fármacos Cardiovasculares/uso terapêutico , LDL-Colesterol/sangue , Infecções por HIV/complicações , Lipoproteínas LDL/sangue , Poliaminas/uso terapêutico , Tromboplastina/análise , Adulto , Doenças Cardiovasculares/prevenção & controle , Infecções por HIV/tratamento farmacológico , Humanos , Receptores de Lipopolissacarídeos/sangue , Lipopolissacarídeos/sangue , Masculino , Pessoa de Meia-Idade , Sevelamer , Resultado do Tratamento , Adulto JovemRESUMO
In October of 2020, researchers from around the world met online for the sixth annual International Workshop on Microbiome in HIV Pathogenesis, Prevention, and Treatment. New research was presented on the roles of the microbiome on immune response and HIV transmission and pathogenesis and the potential for alterations in the microbiome to decrease transmission and affect comorbidities. This article presents a summary of the findings reported.
Assuntos
Infecções por HIV , Microbiota , Comorbidade , Infecções por HIV/prevenção & controle , Humanos , Microbiota/fisiologiaRESUMO
In October of 2019, researchers and community members from around the world met at the NIH for the fifth annual International Workshop on Microbiome in HIV. New research was presented on the role of the microbiome on chronic inflammation and vaccine design, interactions of genetics, environment, sexual practice and HIV infection with the microbiome and the development and clinical trials of microbiome-based therapeutic approaches intended to decrease the probability of HIV acquisition/transmission or ameliorate sequelae of HIV. The keynote address by Dr. Jacques Ravel focused on his work on the vaginal microbiome and efforts to improve the analysis and resolution of microbiome data.